Nationwide Fund Advisors’s ImmunityBio IBRX Stock Holding History

Nationwide Fund Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-17,302	Closed	-$95K	–	978
2017 Q3	$95K	Hold	17,302	–	–	﹤0.01%	2920
2017 Q2	$131K	Buy	17,302 +6,977	+68%	+$30.1K	﹤0.01%	2790
2017 Q1	$37K	Hold	10,325	–	–	﹤0.01%	3030
2016 Q4	$59K	Hold	10,325	–	–	﹤0.01%	2986
2016 Q3	$80K	Hold	10,325	–	–	﹤0.01%	2961
2016 Q2	$64K	Buy	10,325 +5,471	+113%	+$42.5K	﹤0.01%	3042
2016 Q1	$40K	Buy	4,854 +834	+21%	+$7.86K	﹤0.01%	3023
2015 Q4	$70K	Buy	4,020 +2,826	+237%	+$41.9K	﹤0.01%	2933
2015 Q3	$14K	Buy	+1,194	New	+$26.1K	﹤0.01%	3153

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nationwide Fund Advisors's IBRX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of ImmunityBio (IBRX) in Q4 2017, closing a stake of 17,302 shares — an estimated $95K sold.

Nationwide Fund Advisors first reported a position in IBRX in Q3 2015 and held it in 9 quarters. The position peaked at $131K in Q2 2017. 63 funds tracked by Wall St. Rank hold IBRX as of Q4 2017.

Nationwide Fund Advisors reported no remaining ImmunityBio position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 17,302 ImmunityBio shares in Q4 2017, an estimated $95K.
Nationwide Fund Advisors first reported a position in ImmunityBio in Q3 2015 and held it in 9 quarters.
Nationwide Fund Advisors's ImmunityBio position peaked at $131K in Q2 2017.
63 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.